Dr amy prawira

Aggarwal C; Prawira A; Antonia S; Rahma O; Tolcher A; Cohen RB; Lou Y; Hauke R; Vogelzang N; P Zandberg D; Kalebasty AR; Atkinson V; Adjei AA; Seetharam M; Birnbaum A; Weickhardt A; Ganju V; Joshua AM; Cavallo R; Peng L; Zhang X; Kaul S; Baughman J; Bonvini E; Moore PA; Goldberg SM; Arnaldez FI; Ferris RL; Lakhani NJ, 2022, 'Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: Interim results from a multicenter phase I/II trial', Journal for ImmunoTherapy of Cancer, vol. 10, http://dx.doi.org/10.1136/jitc-2021-004424

Schöffski P; Tan DSW; Martín M; Ochoa-De-Olza M; Sarantopoulos J; Carvajal RD; Kyi C; Esaki T; Prawira A; Akerley W; De Braud F; Hui R; Zhang T; Soo RA; Maur M; Weickhardt A; Krauss J; Deschler-Baier B; Lau A; Samant TS; Longmire T; Chowdhury NR; Sabatos-Peyton CA; Patel N; Ramesh R; Hu T; Carion A; Gusenleitner D; Yerramilli-Rao P; Askoxylakis V; Kwak EL; Hong DS, 2022, 'Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies', Journal for ImmunoTherapy of Cancer, vol. 10, http://dx.doi.org/10.1136/jitc-2021-003776

Lim J; Akbar Ali S; Prawira A; Sim HW, 2021, 'Impact of travel distance on outcomes for clinical trial patients: the Kinghorn Cancer Centre experience', Internal Medicine Journal, http://dx.doi.org/10.1111/imj.15561

Oliva M; Chepeha D; Araujo DV; Diaz-Mejia JJ; Olson P; Prawira A; Spreafico A; Bratman SV; Shek T; De Almeida J; R Hansen A; Hope A; Goldstein D; Weinreb I; Smith S; Perez-Ordoñez B; Irish J; Torti D; Bruce JP; Wang BX; Fortuna A; Pugh TJ; Der-Torossian H; Shazer R; Attanasio N; Au Q; Tin A; Feeney J; Sethi H; Aleshin A; Chen I; Siu L, 2021, 'Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study', Journal for ImmunoTherapy of Cancer, vol. 9, http://dx.doi.org/10.1136/jitc-2021-003476

Day D; Prawira A; Spreafico A; Waldron J; Karithanam R; Giuliani M; Weinreb I; Kim J; Cho J; Hope A; Bayley A; Ringash J; Bratman SV; Jang R; O'Sullivan B; Siu LL; Hansen AR, 2020, 'Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck', Oral Oncology, vol. 108, http://dx.doi.org/10.1016/j.oraloncology.2020.104753

Gallagher RM; Pattatheyil A; Pantvaidya GH; Panizza BJ; Sharan R; Deshmukh AD; Barnett CME; Swart DJ; Mynott TL; Cleal A; Gordon V; Prawira A, 2020, '974TiP Exploratory phase Ib/IIa study of intratumorally administered tigilanol tiglate to assess safety, tolerability and tumour response in patients with head and neck squamous cell carcinoma', Annals of Oncology, vol. 31, pp. S684 - S684, http://dx.doi.org/10.1016/j.annonc.2020.08.1089

Joshua AM; Prawira A; Thavaneswaran S; Cosman R; Lee CK; Sjoquist KM; Simes J; Thomas DM; Espinoza D; Sebastian L; Ballinger ML; Hague W; Chinchen S; Collignon E; Kansara M; Palacios T; Grady J; Barker H; Thornton K, 2020, 'A signal-seeking trial of olaparib and durvalumab in homologous repair-deficient tumors: A sub-study of the cancer molecular screening and therapeutics (MoST) program.', Journal of Clinical Oncology, vol. 38, pp. 3073 - 3073, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3073

Millward M; Frentzas S; Gan HK; Prawira A; Tran B; Coward J; Jin X; Li B; Wang M; Kwek KY; Xia Y; Desai J, 2020, 'Safety and antitumor activity of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with mesothelioma which is relapsed or refractory to standard therapies', ANNALS OF ONCOLOGY, vol. 31, pp. S705 - S706, http://dx.doi.org/10.1016/j.annonc.2020.08.1141

Mislang ARA; Coward J; Cooper A; Underhill CR; Zheng Y; Xu N; Xiao C; Jin X; Li B; Wang M; Kwek KY; Xia D; Xia Y; Prawira A, 2020, 'Efficacy and safety of penpulimab (AK105), a new generation anti-programmed cell death-1 (PD-1) antibody, in upper gastrointestinal cancers', ANNALS OF ONCOLOGY, vol. 31, pp. S1300 - S1301, http://dx.doi.org/10.1016/j.annonc.2020.10.178

Oliva Bernal M; Araujo DV; Chepeha DB; Prawira A; Spreafico A; Bratman SV; Shek T; de Almeida JR; Hansen AR; Hope AJ; Goldstein DP; Weinreb I; Perez-Ordonez B; Pugh TJ; Ohashi PS; Wang BX; Irish JC; Der-Torossian H; Chen I; Siu LL, 2020, 'SNOW: Sitravatinib and nivolumab in oral cavity cancer (OCC) window of opportunity study.', Journal of Clinical Oncology, vol. 38, pp. 6569 - 6569, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.6569

Prawira A; Coward J; Mislang A; Nagrial A; Gan H; Jin X; Li B; Wang ZM; Kwek KY; Xia D; Xia Y, 2020, '384 A Phase 1 study to evaluate the safety, PK, and antitumor activity of AK117, an anti-CD47 monoclonal antibody, in subjects with relapsed/refractory advanced or metastatic solid tumors or lymphomas', Regular and young investigator award abstracts, vol. 8, pp. A409 - A409, http://dx.doi.org/10.1136/jitc-2020-sitc2020.0384

Hansen AR; Tannock IF; Templeton A; Chen E; Evans A; Knox J; Prawira A; Sridhar SS; Tan S; Vera-Badillo F; Wang L; Wouters BG; Joshua AM, 2019, 'Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC)', Oncologist, vol. 24, pp. 1188 - 1194, http://dx.doi.org/10.1634/theoncologist.2018-0621

Mehnert JM; Varga A; Brose MS; Aggarwal RR; Lin CC; Prawira A; De Braud F; Tamura K; Doi T; Piha-Paul SA; Gilbert J; Saraf S; Thanigaimani P; Cheng JD; Keam B, 2019, 'Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer', BMC Cancer, vol. 19, http://dx.doi.org/10.1186/s12885-019-5380-3

Stradella A; Johnson ML; Goel S; Chandana SR; Galsky MD; Calvo E; Moreno V; Park H; Arkenau H-T; Cervantes A; Madrid LF; Mileshkin L; Plummer R; Evans J; Horvath L; Prawira A; Pelham RJ; Mu S; Andreu-Vieyra C; Barve M, 2019, 'Updated results of the PARP1/2 inhibitor pamiparib in combination with low-dose (ld) temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumours', Annals of Oncology, vol. 30, pp. v166 - v167, http://dx.doi.org/10.1093/annonc/mdz244.013

Hong DS; Schoffski P; Calvo A; Sarantopoulos J; De Olza MO; Carvajal RD; Prawira A; Kyi C; Esaki T; Akerley WL; De Braud FG; Hui R; Zhang T; Soo RA; Maur M; Weickhardt AJ; Chowdhury NR; Sabatos-Peyton C; Kwak EL; Tan DS-W, 2018, 'Phase I/II study of LAG525 +/- spartalizumab (PDR001) in patients (pts) with advanced malignancies.', JOURNAL OF CLINICAL ONCOLOGY, vol. 36, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.3012

George M; Mandaliya H; prawira A, 2017, 'A survey of medical oncology training in Australian Medical Schools: pilot study', JMIR Medical Education, vol. 12, pp. e23 - e23, http://dx.doi.org/10.2196/mededu.7903

Infante JR; Bedard PL; Shapiro G; Bauer TM; Prawira A; Laskin O; Weetall M; Baird J; Branstrom A; O'Mara E; Spiegel RJ, 2017, 'Phase 1 results of PTC596, a novel small molecule targeting cancer stem cells (CSCs) by reducing levels of BMI1 protein.', Journal of Clinical Oncology, vol. 35, pp. 2574 - 2574, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.2574

Prawira A; Lazinski D; Siu LL; Perez-Ordonez B, 2017, 'Giant Prolactinoma Presenting As a Base of Skull Tumor With Nasopharyngeal Extension: A Potential Diagnostic Pitfall in Neuroendocrine Lesions of the Base of Skull', Head and Neck Pathology, vol. 11, pp. 537 - 540, http://dx.doi.org/10.1007/s12105-017-0782-5

Prawira A; Oosting SF; Chen TW; Delos Santos KA; Saluja R; Wang L; Siu LL; Chan KKW; Hansen AR, 2017, 'Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review', British Journal of Cancer, vol. 117, pp. 1743 - 1752, http://dx.doi.org/10.1038/bjc.2017.357

Prawira A; Pugh TJ; Stockley TL; Siu LL, 2017, 'Data resources for the identification and interpretation of actionable mutations by clinicians', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 28, pp. 946 - 957, http://dx.doi.org/10.1093/annonc/mdx023

Prawira A; Stundzia AB; Dufort P; Halankar J; Paravasthu DM; Spreafico A; Hansen AR; Abdul Razak AR; Bedard PL; Butler M; Lheureux S; Oza AM; Jang RW; Suta KM; Boross-Harmer S; Cipollone J; Chow H; Metser U; Siu LL, 2017, 'Evaluation of a predictive radiomics signature for response to immune checkpoint inhibitors (ICIs)', Annals of Oncology, vol. 28, pp. v31 - v31, http://dx.doi.org/10.1093/annonc/mdx363.031

Wong H-L; Luechtefeld T; Prawira A; Patterson Z; Workman J; Day D; Chooback N; Nappi L; Samawi HH; Lavoie J-M; Spreafico A; Hansen AR; Sahebjam S; Siu LL; Ivy SP; Paller C; Renouf D, 2017, 'Development of a web-based application using machine learning algorithms to facilitate systematic literature reviews', Annals of Oncology, vol. 28, pp. v518 - v518, http://dx.doi.org/10.1093/annonc/mdx385.023

Mehnert JM; Varga A; Brose M; Aggarwal RR; Lin C-C; Prawira A; de Braud F; Tamura K; Doi T; Piha-Paul SA; Gilbert J; Saraf S; Thanigaimani P; Cheng JD; Keam B, 2016, 'Pembrolizumab for advanced papillary or follicular thyroid cancer: preliminary results from the phase 1b KEYNOTE-028 study.', Journal of Clinical Oncology, vol. 34, pp. 6091 - 6091, http://dx.doi.org/10.1200/jco.2016.34.15_suppl.6091

Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak ARA; Chen EX; Jang R; O’Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR, 2016, 'Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001)', Investigational New Drugs, vol. 34, pp. 575 - 583, http://dx.doi.org/10.1007/s10637-016-0367-2

Prawira A; Dufort P; Halankar J; Paravasthu DM; Hansen A; Spreafico A; Razak ARA; Chen E; Jang RW; Metser U; Siu LL, 2016, 'Development of a predictive radiomics signature for response to immune checkpoint inhibitors (ICIs) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN)', Annals of Oncology, vol. 27, pp. vi330, http://dx.doi.org/10.1093/annonc/mdw376.08

Prawira A; Oosting S; Chen TW-W; Saluja R; Delos Santos K; Wang L; Siu LL; Chan KK; Hansen AR, 2016, 'Systemic therapies for recurrent/metastatic nasopharyngeal carcinoma (RM NPC).', Journal of Clinical Oncology, vol. 34, pp. 6031 - 6031, http://dx.doi.org/10.1200/jco.2016.34.15_suppl.6031

Shapiro G; Bedard P; Infante J; Bauer T; Prawira A; Laksin O; Weetall M; Baird J; Branstrom A; O'Mara E; Spiegel R, 2016, 'Phase 1 results of PTC596, a novel small molecule targeting cancer stem cells (CSCs) by reducing levels of BMI1 protein', European Journal of Cancer, vol. 69, pp. S148 - S148, http://dx.doi.org/10.1016/s0959-8049(16)33039-8

Shapiro G; Infante J; Bauer TM; Prawira A; Bedard P; Laskin O; Weetall M; Baird J; O'Mara E; Spiegel R, 2016, 'Initial first-in-human phase 1 results of PTC596, a novel small molecule that targets cancer stem cells (CSCs) by reducing BMI1 protein levels', Annals of Oncology, vol. 27, pp. vi122, http://dx.doi.org/10.1093/annonc/mdw368.27

Mandaliya H; Baghi P; Prawira A; George MK, 2015, 'A Rare Case of Paclitaxel and/or Trastuzumab Induced Acute Hepatic Necrosis.', Case Rep Oncol Med, vol. 2015, pp. 825603, http://dx.doi.org/10.1155/2015/825603

George M; Ngo P; Prawira A, 2014, 'Rural oncology: Overcoming the tyranny of distance for improved cancer care', Journal of Oncology Practice, vol. 10, pp. e146 - e149, http://dx.doi.org/10.1200/JOP.2013.001228

Wong MLH; Prawira A; Kaye AH; Hovens CM, 2009, 'Tumour angiogenesis: Its mechanism and therapeutic implications in malignant gliomas', Journal of Clinical Neuroscience, vol. 16, pp. 1119 - 1130, http://dx.doi.org/10.1016/j.jocn.2009.02.009

Hernando-Calvo A; Malone E; Day D; Prawira A; Weinreb I; Wong H; Rodriguez A; Jennings S; Eliason A; Wang L; Spreafico A; Siu LL; Hansen A, 2022, Selinexor for the treatment of recurrent or metastatic salivary gland tumors: results from the GEMS-001 clinical trial., http://dx.doi.org/10.21203/rs.3.rs-2114261/v1

Hernando-Calvo A; Malone E; Dai D; Prawira A; Weinreb I; Eliason A; Rodriguez A; Lajkosz K; Jennings S; Spreafico A; Siu LL; Hansen A, 2021, 'Abstract P154: Genomic profiling and matched therapy for recurrent or metastatic salivary gland neoplasms. Results from the matched cohort of the GEMS-001 clinical trial', in Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), pp. P154 - P154, presented at Abstracts: AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; October 7-10, 2021, http://dx.doi.org/10.1158/1535-7163.targ-21-p154

Markman B; Day D; Park JJW; Coward J; Bishnoi S; Kotasek D; Eek R; Brown MP; Lemech C; Kuo J; Prawira A; Strother R; Zhang Q; Wang L; Chen R; Ma Y; Qin Z; Tse A, 2020, 'Preliminary pharmacokinetics (PK), safety and efficacy of two dosing regimens of CS1003 (anti-PD-1) in solid tumours: 200 mg every 3-week (Q3W) and 400 mg every 6-week (Q6W) dosing', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 31, pp. S722 - S722, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.1177

Stradella A; Johnson M; Goel S; Chandana SR; Galsky MD; Calvo E; Moreno V; Park H; Arkenau T; Cervantes A; Farinas-Madrid L; Mileshkin L; Fu S; Plummer R; Evans J; Horvath L; Prawira A; Qu K; Pelham R; Barve MA, 2020, 'Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumours treated with the PARP1/2 inhibitor pamiparib in combination with low-dose (LD) temozolomide (TMZ)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 31, pp. S465 - S466, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.644

Bernal MO; Chepeha D; Prawira A; Vines D; Spreafico A; Bratman S; Almeida JD; Hansen A; Goldstein D; Gilbert R; Gullane P; Brown DH; Weinreb I; Perez-Ordoñez B; Ohashi PS; McGaha T; Wang BX; Irish J; Chen I; Siu LL, 2019, 'Abstract CT124: Sitravatinib and nivolumab in oral cavity cancer window of opportunity study (SNOW)', in Clinical Trials, American Association for Cancer Research, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.sabcs18-ct124

Bernal MO; Chepeha D; Prawira A; Vines D; Spreafico A; Bratman S; De Almeida J; Hansen A; Goldstein D; Gilbert R; Gullane P; Brown DH; Weinreb I; Perez-Ordonez B; Ohashi PS; McGaha T; Wang BX; Irish J; Chen I; Siu LL, 2019, 'Sitravatinib and nivolumab in oral cavity cancer window of opportunity study (SNOW)', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-CT124

Kotasek D; Coward J; de Souza PL; Underhill C; Jin X; Li B; Xia Y; Prawira A, 2019, 'A phase I dose escalation and dose expansion study of the anti-programmed cell death-1 (PD-1) antibody AK105.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.e14006

Millward M; Gan HK; Joshua AM; Kuo JC-Y; Prawira A; Richardson GE; Barbee SD; Inamdar SP; Pierce KL; Qureshi M; Horvath L, 2019, 'FPT155-001: A phase Ia/Ib study of FPT155 (CD80-FC) in patients with advanced solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 37, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, CA, San Francisco, 28 February 2019 - 02 March 2019, http://dx.doi.org/10.1200/JCO.2019.37.8_suppl.TPS42

Xu K; Lo A; Chin V; Gzell C; O'Connor C; Forstner D; Gallagher R; Bova R; Crawford J; Harvey R; Lochhead A; Earls P; Qiu MR; Hsu E; Bigg-Wither G; Chan L; Bao H; Foltyn P; Sim HW; Prawira A, 2018, 'Development of overall survival (OS) and progression free survival (PFS) nomograms for Australian patients with locoregionally advanced oropharyngeal squamous cell carcinoma (LA OPSCC)', in Annals of oncology : official journal of the European Society for Medical Oncology, OXFORD UNIV PRESS, Munich, GERMANY, pp. viii389, presented at 43rd ESMO Congress (ESMO), Munich, GERMANY, 19 October 2018 - 23 October 2018, http://dx.doi.org/10.1093/annonc/mdy287.049

George M; Mandaliya H; Prawira A, 2017, A Survey of Medical Oncology Training in Australian Medical Schools: Pilot Study (Preprint), http://dx.doi.org/10.2196/preprints.7903

Hansen A; Tannock I; Templeton AJ; Prawira A; Knox J; Vera-Badillo F; Chen E; Zavitz MB; Wang L; Evans A; Tan Q; Wouters B; Sridhar S; Joshua A, 2016, 'Pantoprazole affecting docetaxel resistance pathways via autophagy (PANDORA): A phase II trial in men with metastatic castrate resistant prostate cancer (mCRPC)', Copenhagen, DENMARK, Vol. 27, pp. vi249, presented at 41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, DENMARK, 07 October 2016 - 11 October 2016, http://dx.doi.org/10.1093/annonc/mdw372.20

Hansen AR; Tannock I; Prawira A; Knox JJ; Templeton AJ; Vera-Badillo F; Chen EX; Zavitz M-B; Wang L; Evans A; Tan S; Wouters B; Sridhar SS; Joshua AM, 2016, 'Pantoprazole affecting docetaxel resistance pathways via autophagy (PANDORA): a phase II trial in men with castration resistant prostate cancer (mCRPC).', IL, Chicago, Vol. 34, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.e16502